Global Companion Animal Pharmaceuticals Market Assessment, By Animal Type [Dogs, Cats, Horses, Others], By Indication [Infectious Disease, Dermatologic Disease, Parasitic Infection, Orthopedic Disease, Others], By Route of Administration [Oral, Injectable, Topical], By Distribution Channel [Veterinary Hospitals and Clinics, Retail Pharmacies, Others], By Region, Opportunities and Forecast, 2018-2032F

Global Companion animal pharmaceuticals market is projected to witness a CAGR of 9.15% during the forecast period 2025-2032, growing from USD 20.91 billion in 2024 to USD 42.14 billion in 2032. The market’s growth is supported by the increasing adoption of companion animals, the introduction of supportive initiatives and policies globally, rising disposable incomes, increasing investments in veterinary pharmaceuticals, and growing availability of pet insurance.

Report Attribute	Details
Base Year of the Analysis	2024
Historical Period	2018-2023
Forecast Period	2025-2032
Projected Growth Rate	CAGR of 9.15% between 2025 and 2032
Revenue Forecast in 2032	USD 42.14 billion

The market’s growth is also supported by the increasing investments in technological innovations in veterinary diagnostic solutions. The introduction of advanced diagnostic solutions ensures the timely detection of various diseases, allowing pet owners to seek medical attention and therapeutic intervention for their pets in a time-efficient manner. As veterinary technologies evolve, the delivery of novel drug delivery systems and targeted therapies is increasing, ensuring improved disease management. The rising emphasis on innovation and research activities, coupled with growing awareness about companion animal health and the broader availability of pet insurance, is also bolstering the market’s expansion.

New Product Investments Drive Growth Opportunities in the Market

Increasing investments in new launches are providing lucrative growth opportunities for the market by ensuring the availability of convenient, effective, and innovative products that support the evolving requirements of veterinarians and pet owners. Such launches often include advanced formulations, such as oral tick and flea treatments, as well as specialized therapeutics that target infectious and chronic diseases in pets. Additionally, rapid innovations in nutraceuticals, personalized medicines, and drug delivery systems are improving efficacy and adherence, ensuring wider adoption and positively influencing the market’s expansion. Thus, various companies globally are focusing on launching products that facilitate easy adherence.

For instance, in April 2024, Boehringer Ingelheim International GmbH launched NexGard SPECTRA in India, following the approval by the Central Drugs Standard Control Organization (CDSCO). The soft chew provides a comprehensive range of external and internal parasite control in a single dose, administered monthly. The prescription-only product contains milbemycin oxime, which controls intestinal worms and provides protection against heartworm, as well as afoxolaner, which targets ticks and fleas.

Increasing Pet Insurance Boosts Global Companion Animal Pharmaceuticals Market Growth

As more pet owners are purchasing pet insurance, the financial barriers to pharmaceutical products for companion animals are being eliminated, resulting in increased demand for therapeutic and preventive purposes. Insurance coverage includes reimbursement for prescription medications, wellness visits, and management of chronic and infectious diseases, increasing accessibility for pet owners to high-quality and specialized pharmaceutical solutions.

As per the North America Pet Health Insurance Association, in 2024, the United States experienced a 12.7% growth in the total number of pets insured compared to 2023. With insurance, pet owners are more likely to seek timely veterinary intervention and adhere to prescribed treatment regimens, directly boosting demand for pharmaceuticals. Additionally, as the emotional bonds between pet owners and their companion animals increase, they are more likely to focus on their health and well-being, resulting in them providing their companion animals with regular check-ups and treatment interventions, which provide lucrative growth opportunities for the market.

Veterinary Hospitals and Clinics Hold Major Market Share

The segment’s dominance can be attributed to the presence of advanced healthcare infrastructure, skilled professionals, and a comprehensive range of treatments and services across veterinary hospitals and clinics. Additionally, these facilities are equipped with advanced laboratory capabilities, surgical equipment, and diagnostic tools, allowing them to provide precise diagnoses and effectively treat a wide range of conditions in companion animals. The presence of skilled veterinarians ensures that pets receive specialized care, including the administration of pharmaceuticals, vaccinations, and preventive medications tailored to the specific requirements of companion animals. Thus, governments worldwide are increasingly funding veterinary hospitals and clinics to ensure that the animal population receives optimal care.

For instance, in May 2025, Oklahoma State University received USD 250 million in state funding to build a new veterinary hospital. Such investments are strengthening clinical capabilities, veterinary education, and research infrastructure, thereby propelling the demand for companion animal pharmaceuticals and positively influencing the market’s expansion.

North America Dominates the Global Companion Animal Pharmaceuticals Market Growth

The market’s rapid expansion in North America can be attributed to the rising adoption of companion animals in the region, the strong presence of leading market players, and high awareness about veterinary care practices and treatments. As per the estimates of the American Society for the Prevention of Cruelty to Animals (ASPCA), 4.2 million shelter animals were adopted in the United States in 2024. Furthermore, the region’s rising innovations in companion animal medicines in the region, driven by the strong presence of various research organizations and institutions focused on veterinary care, are also providing lucrative growth opportunities for the market. Additionally, increasing consumer awareness about pet surgeries and various treatment solutions, coupled with the rising availability of pet insurance, is further bolstering the demand for pharmaceutical products for companion animals. Pet insurance plays a crucial role in helping pet owners manage pharmaceutical costs and other essential expenses that are vital for ensuring the health and well-being of their companion animals.

Download Free Sample Report

Impact of the U.S. Tariff on the Global Companion Animal Pharmaceuticals Market

The recently imposed tariffs are causing unrest in supply chains as the companion animal pharmaceuticals market relies heavily on international channels for sourcing the necessary raw materials, including biologics and antigens. Additionally, the growing threat of retaliatory tariffs is expected to result in reduced profit margins for the manufacturers and lead to additional operational uncertainties.

To mitigate the impact of the tariff, leading market players are focusing on shifting their supplier base; however, this shift is triggering an increased requirement for new regulatory filings and approvals, causing further disruptions in the supply chain.

Report Scope

“Global Companion Animal Pharmaceuticals Market Assessment, Opportunities and Forecast, 2018-2032F” is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global companion animal pharmaceuticals market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, highlighting their respective market shares, business models, and competitive intelligence.

Report Attribute	Details
Segments Covered	Animal Type, Indication, Route of Administration, Distribution Channel
Regions Covered	North America, Europe, South America, Asia-Pacific, the Middle East, and Africa
Key Companies Profile	Zoetis Services LLC, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Elanco, Virbac, Ceva, Vetoquinol, Dechra Pharmaceuticals PLC, Orion Group Holdings, Inc., Neogen Corporation
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, the global companion animal pharmaceuticals market has been segmented into the following categories: 

• By Animal Type
  • Dogs
  • Cats
  • Horses
  • Others
• By Indication
  • Infectious Disease
  • Dermatologic Disease
  • Parasitic Infection
  • Orthopedic Disease
  • Others
• By Route of Administration
  • Oral
  • Injectable
  • Topical
• By Distribution Channel
  • Veterinary Hospitals and Clinics
  • Retail Pharmacies
  • Others
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

Key players in the market are launching new products and technologies, engaging in mergers and acquisitions to expand their product portfolios and geographical presence, and increasing their revenue.

For instance, in September 2024, Elanco received approval from the US FDA for Zenrelia, an effective, safe, and convenient oral JAK inhibitor for controlling atopic dermatitis and pruritus associated with allergic dermatitis in dogs that are 12 months or older.

Additionally, the key players of the market are also engaging in mergers and acquisitions to support innovations in pet therapeutics. For instance, in January 2024, Ceva acquired Scout Bio, Inc., enhanced its biotechnology activities and developed preventive and biological medicines. Such acquisitions are also expected to bolster the development and availability of biotherapeutics for companion animals.

Key Players Operating in the Global Companion Animal Pharmaceuticals Market are:

• Zoetis Services LLC
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Elanco
• Virbac
• Ceva
• Vetoquinol
• Dechra Pharmaceuticals PLC
• Orion Group Holdings, Inc.
• Neogen Corporation

 

If you can't find what you're searching for or have any custom requirements for the global companion animal pharmaceuticals market, you may approach our team at info@marketsandata.com